Option chain shows key data for Snipp Interactive's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Snipp Interactive.

Snipp Interactive (OTC:SNIPF) Stock, Option Chain

Snipp Interactive Inc a loyalty and promotions technology company develops and sells mobile-based promotions software applications and associated campaign services. The company provides its products in a range of solution sets, which include Purchase Promotions and Receipt Processing; Loyalty Programs; Mobile Promotions and Contests; Reward Solutions; Rebate Solutions, and Data Analytics. It offers software applications that allow advertising agencies, brands, and media to engage and interact with customers. Geographically it operates in several cities in the United States, and international operations in Canada, and Ireland. It derived the majority of its revenues from Ireland.

News

Penny Stocks

Small Cap

BALY

SNIPF

Bally&#39;s Acquires 9% Stake In Snipp Interactive

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AKER

APEN

BBLS

BHAT

BTSC

BYDDF

CADMF

CAPR

CDYCF

CNBX

CORV

CPHRF

CRMBQ

CTSO

CVSI

CXRXF

DELRF

DIGAF

DKAM

DRRSF

ELLXF

EPEGQ

ERBA

EVIO

FPAFF

FPAFY

FTEG

GBLTF

GCAN

GCPEF

GNAL

GNLN

GOHE

GRSO

HRCXF

HRLDF

ICNAF

IPSEY

IQST

IWSY

JMEI

KOIOS BEVERAGE CORP by Koios Beverage Corp.

KBEVF

KFFLF

KPAY

LATF

LFER

LTTSF

LXRP

MCUIF

MENEF

MFCSF

MINE

MJARF

MLHC

MNVWF

MOBI724 GLOB SOLUTNS INC by MOBI724 GLOBAL SOLUTIONS INC

MOBIF

NECA

NGPHF

NXGWF

NXTTF

ORHOF

ORVMF

PENMF

PFMT

PLRTF

PNBK

QRTEB

RGBP

RIGH

RROTF

RSPI

SAPX

SFET

SKXJF

SLXXF

SOHFF

SURJF

SXTC

SYNL

SYZLF

TGGI

TNMLF

TNXP

TPAC

TRSSF

TTNUF

UDHI

VCSY

VGMIF

VREOF

VVDB

WCUI

WDRP

WKULF

YEXT

Stocks That Hit 52-Week Lows On Friday

AAME

ARCH BIOPARTNERS INC ORD by Arch Biopartners Inc.

ACHFF

AGEEF

AGRX

AHPI

ASCOT RESOURCES LTD by Ascot Resources Ltd.

AOTVF

ARLP

ARNI

ARTH

BOGN

BRGGF

CATI

CLVS

CONC

CPST

CSRH

CTMX

CYIG

DFMTF

DYNT

EBODF

EEVVF

EGTYF

ENCTF

FTXP

GFNL

GGAZF

GOTRF

GTSIF

GXOCF

GXXM

HOTH

IPWG

LENSF

AMERICAN LITHIUM CORP ORD by American Lithium Corp.

LIACF

LVVV

MGPHF

MIRM

MLLOF

MNGGF

MRRMF

MYOV

MYSZ

NOSOF

NUGL

OTIV

PHCEF

PIRE

RMIOF

SAPIF

SOLCF

SXEEQ

TACO

TCHH

UVSE

VEGYF

VEND

VIRA

VQSLF

WLDFF

WORK

WTRH

XELA

PNRXF

IBIO

NSHSF

LBHRF

LUCC

ERRCF

RETCD

LINUF

Stocks That Hit 52-Week Lows On Monday

SNIPP INTERACTIVE INC by Snipp Interactive Inc

Snipp Interactive Inc

The global plant-based Active Pharmaceutical Ingredient (API) market is projected to grow at a steady pace, reaching a valuation of $52.1 billion by 2034, according to a <a href="https://www.futuremarketinsights.com/reports/plant-based-api-market">new report</a> by Future Market Insights. The industry is expected to expand at a Compound Annual Growth Rate (CAGR) of 5.6%, fueled by rising demand for natural and sustainable pharmaceutical solutions, including <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a> and <a href="https://www.benzinga.com/topic/cannabis-products">cannabis-derived</a> compounds.
<h3 class="wp-block-heading">Rising Demand For Psychedelic And Cannabis-Based Ingredients</h3>
A significant driver of market growth is the increasing use of psychoactive and plant-derived substances in modern pharmacology. Psychedelics like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and cannabinoids such as <a href="https://www.benzinga.com/topic/cbd">CBD</a> and <a href="http://v">THC</a> are gaining attention for their <a href="http://v">therapeutic potential</a> in mental health and oncology. The U.S., a key player in the market, is leveraging biotechnological advances like <a href="https://www.genome.gov/genetics-glossary/CRISPR#:~:text=CRISPR%20(short%20for%20%E2%80%9Cclustered%20regularly,editing%20systems%20found%20in%20bacteria.">CRISPR</a> and synthetic biology to scale production of these high-demand APIs, contributing to a 4.2% CAGR.
"The global shift toward sustainable, plant-based solutions reflects both consumer interest in natural medicine and the pharmaceutical industry's focus on alternative therapies," said Sabyasachi Ghosh, associate VP at Future Market Insights. The market&#8217;s rapid expansion underscores the increasing acceptance of psychedelics and cannabis as mainstream pharmaceutical ingredients.
<h3 class="wp-block-heading">Therapeutic Applications And Key Botanical Sources</h3>
Plant-based APIs are harnessed from well-documented medicinal plants such as cannabis, ginseng, turmeric and cinchona. These natural sources contain bioactive compounds like flavonoids, terpenes and alkaloids, offering various therapeutic benefits. Major applications of plant-based APIs include pain management, anti-inflammatory treatments and oncology therapies.
The incorporation of cannabinoids, particularly CBD and THC, into pharmaceutical formulations is reshaping the landscape of pain and anxiety treatments. Similarly, psychoactive compounds from plants like Syrian rue and Psilocybe mushrooms are being explored for treating mental health disorders like depression and PTSD.
<h3 class="wp-block-heading">Regional Growth And Market Segmentation</h3>
The report highlights robust growth in Asian markets, with India leading at an 8.8% CAGR, followed closely by China (8.7%) and South Korea (8.6%). These regions are investing heavily in agricultural biotechnologies and expanding their capabilities in plant-based pharmaceutical production.
The market segments by product type, covering alkaloids, cannabinoids, <a href="https://www.benzinga.com/markets/cannabis/24/05/39064102/cannabis-terpenes-alleviate-chemo-induced-neuropathic-pain-study-shows-added-benefits-with-morph">terpenes</a>, flavonoids and polyphenols. It also includes API forms like extracts, powders and resins from botanicals such as opium poppy, turmeric, ginseng and cannabis.
<h3 class="wp-block-heading">Competitive Landscape: Psychedelics And Cannabis Companies Lead the Charge</h3>
The plant-based API sector is experiencing intense competition, particularly in the cannabis and psychedelics segments. Companies are rapidly scaling production and forming key partnerships to meet the rising demand for plant-based, pharmaceutical-grade ingredients.
Recent developments include Bright Green Corporation's agreement to supply <a href="https://www.benzinga.com/24/02/37292778/dea-clears-this-nasdaq-traded-plant-touching-firm-to-research-and-produce-schedule-i-and-ii-plant-ba">DEA-approved marijuana</a> extracts and psychedelic compounds to Benuvia Operations. Indena's authorization from Italian regulators to produce pharmaceutical-grade CBD further illustrates the expanding global footprint of cannabis-derived APIs.
Key players in the industry include the Illinois-based Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), New Mexico&#8217;s Bright Green Corporation, Indena S.p.A., headquartered in Milan, Italy, Alchem International Pvt. Ltd., based in India, Israeli Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>); Roquette Frères, based in Lestrem, France; and Sami-Sabinsa Group, based in New Jersey.
<h3 class="wp-block-heading">The Future Of Plant-Based APIs: Sustainable And Psychedelic Solutions</h3>
The growing demand for sustainable, natural treatments will likely position the plant-based API market at the forefront of global healthcare. As pharmaceutical companies continue to explore the therapeutic potential of bioactive compounds from plants, the integration of psychedelics and cannabis-derived APIs is likely to play a pivotal role in shaping the next decade of medicine.
Cover image made with AI

Cannabis

Market Summary

Psychedelics

Global

TEVA

Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids

SpaceX, under the leadership of Elon Musk, is reportedly preparing to initiate a tender offer next month.
What Happened: SpaceX's tender offer will allow the sale of existing shares at $135 each, valuing the company at over $250 billion, as reported by Reuters.
Musk&#8217;s ambition for human Mars exploration could become a national priority under Trump&#8217;s administration. The NASA Artemis program, which intends to use SpaceX&#8217;s Starship for lunar missions as a precursor to Mars expeditions, is anticipated to shift focus towards Mars with uncrewed missions targeted this decade.
SpaceX might push for relaxed regulations on worker and participant safety in private space flights under Trump&#8217;s presidency.
An investigation last year revealed over 600 worker injuries at SpaceX facilities, <a href="https://www.benzinga.com/news/24/04/38374353/elon-musks-spacex-injury-rates-exceed-industry-average-again-raising-concerns-for-nasa-and-clients-r">exceeding the industry average</a>, raising concerns about the company&#8217;s adherence to safety standards.
See Also: <a href="https://www.benzinga.com/trading-ideas/24/11/41985486/if-tesla-stock-hits-all-time-highs-in-2025-will-it-be-driven-by-trump-musk-relationship-benzinga-readers-say-this?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If Tesla Stock Hits All-Time Highs In 2025, Will It Be Driven By Trump-Musk Relationship?</a>
Why It Matters: SpaceX&#8217;s valuation has seen a significant increase over the past year. In June, the company was reportedly set for a <a href="https://www.benzinga.com/news/24/06/39516906/elon-musks-spacex-set-for-record-210b-valuation-in-tender-offer-but-still-valued-less-than-tiktok-re">record $210 billion</a> valuation in a tender offer, surpassing its previous $200 billion estimate. This was driven by substantial investor demand.
However, Musk has <a href="https://www.benzinga.com/news/24/06/39519229/elon-musk-dismisses-rumors-of-spacex-ipo-as-it-reportedly-seeks-210b-valuation-pressure-for-short-te">previously dismissed</a> the possibility of a SpaceX initial public offering (IPO), citing the intense pressure for short-term results faced by publicly listed companies.
SpaceX&#8217;s dominance in the space sector is further highlighted by its control over <a href="https://www.benzinga.com/news/24/09/40869627/elon-musk-now-controls-two-thirds-of-the-planets-satellites-and-spacex-is-just-getting-started-with">two-thirds of the planet&#8217;s satellites</a>, thanks to the rapid expansion of its Starlink satellite network.
As of September, SpaceX&#8217;s Starlink service <a href="https://www.benzinga.com/news/24/09/41061483/spacexs-starlink-now-connects-4m-customers-with-more-than-6k-operational-satellites-adds-a-million-u">connects over 4 million customers</a> worldwide, demonstrating the company&#8217;s significant impact on global connectivity.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41973501/teslas-profit-power-vs-rivians-cash-burn-can-the-gap-be-narrowed?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Profit Power Vs. Rivian&#8217;s Cash Burn: Can The Gap Be Narrowed?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

SPACE

SpaceX To Launch Tender Offer, Valuing Company At Over $250 Billion: Report

Comments

Snipp Interactive

Snipp Interactive (SNIPF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga